Members of the Laboratory

Publications

Hsu KC, Liu X, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor (KIR) haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002; 169:5118-5129.

Marsh SGE, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D, Vilches C, Carrington M, Witt C, Guethlein LA, Shilling H, Garcia CA, Hsu KC, Wain H. Killer immunoglobulin-like receptor (KIR) Nomenclature Report, 2002. Immunogenetics 2003; 55:220-226.

Hsu KC, Taylor CA, O'Reilly RJ, Horowitz MM, Arkun K, Pinto C, Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.

Kesh S, Mensah NY, Peterlongo P, Jaffe D, Hsu K, van den Brink M, O'Reilly R, Pamer E, Satagopan J, Papanicolaou GA. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann NY Acad Sci 2005; 1062: 95-103.

Hsu K, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon J, Bornauser M, Christiansen F, Gratwohl A, Morishima Y, Oudshoorn M, Ringden O, van Rood JJ, Petersdorf E, International Histocompatibility Working Group. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrrow Transpl. 2006; 12: 828-836.

Hsu KC, Pinto-Agnello C, Gooley T, Malkki M, Dupont B, Petersdorf EW, IHWG HCT-KIR Component, Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component. Tissue Antigens 2007; 69 Suppl. 1: 1-4.

Small TN, Young JW, Prockop S, Castro-Malaspina H, Wilton A, Heller G, Boulad F, Chiu M, Hsu KC, Jakubowski A, Kernan NA, Perales MA, O'Reilly RJ, Papadopoulos E. Intravenous busulfan and melphalan, tacrolimus and short course methotrexate followed by an unmodified HLA matched related or unrelated hematopoetic stem cell transplant (HSCT) for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transpl., 2007; 13: 235-244.

Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR Ligand Group in vitro. J Immunol. 2007; 179: 854-868.

Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu K, Perales MA, Collins N, Cisek C, Chiu M, van den Brink MRM, O'Reilly RJ, Papadopoulos EB. T-cell depleted stem cell transplantation fro adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of anit-thymocyte globulin. Blood. 2007; 110: 4552-4559.

Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, Heller G, Hsu KC, Perales MA, van den Brink MRM, Young JW, Prockop SE, Collins NH, O'Reilly RJ, Boulad F. Fludarabine-based conditioning secures engraftment of second heamtopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transpl. Biol Blood Marrow Transpl. 2007; 13: 1313-1323.

Yu J, Heller G, Chewning JH, Kim S, Yokoyama W, Hsu KC. Diversity and hierarchy of the human natural killer cell response are determined by inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol. 2007; 179: 5977-89.

Kim S, Sunwoo JB, Yang L, Choi T, Song Y, French AR, Vlahiotis A, Piccirillo JF, Cella M, Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA. 2008; 105: 3053-8.

Castro-Malaspina H, Jakubowski AA, Papdopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ. Induction of remission prior to transplantation improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transpl. 2008; 14:458-468.

Ostronoff F, Perales M-A, Stubblefield MD, Hsu KC. Rituximab-responsive Guillain-Barre Syndrome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 42: 71-2.

Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD, Barlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Brit. J. Hematol. 2008 Oct 16 [Epub ahead of print].

Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O'Reilly RJ, Hsu KC. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function following T-cell depleted allogeneic hematopoietic cell transplantation. Blood. In press.

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2009 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org